Multiple Myeloma Coverage from Every Angle
Advertisement
Advertisement

News

Biweekly Dosing Approved by the FDA for Teclistamab-cqyv in Multiple Myeloma
DREAMM-7 Supports Novel Triplet Regimen in Relapsed or Refractory Multiple Myeloma
Understanding the Clinical Impact of Progressive Smoldering Multiple Myeloma
Initial Trial Results With Novel Combination Therapy for Resistant Myeloma
Is There a Future for Microbiota-Based Treatment in Resistant Multiple Myeloma?
FDA Calls for New Boxed Warning on All CAR T-Cell Therapies
Early Results With Bispecific T-Cell Engager in High-Risk Smoldering Myeloma
NCCN Awards Grants to Study Use of BCMA-Directed Bispecific Antibody in Multiple Myeloma
Has the Risk of Infection Shifted in the Era of Novel Multiple Myeloma Agents?
New BCL2 Inhibitor Plus Dexamethasone Under Study in Relapsed or Refractory Multiple Myeloma
Can Revised FLC Reference Intervals Improve Diagnosis of Light Chain MGUS?
MonumenTAL-1 Trial: Intensity of Dosing With Talquetamab in Myeloma Under Study
Comparing Infections Rates With Bispecific Antibodies in Relapsed or Refractory Multiple Myeloma
ASH 2023: Four-Drug vs Three-Drug Regimens Before and After ASCT in Myeloma
ASH 2023: Quadruplet Regimen Followed by Doublet Maintenance Improves Outcomes in Multiple Myeloma
ASH 2023: Final CENTAURUS Analysis Supports Daratumumab’s Role in Smoldering Myeloma
ASH 2023: Using Inflammatory Biomarkers to Predict Response to CAR T-Cell Therapy
ASH 2023: MRD Negativity With Triplet Therapy in Transplantation-Ineligible Patients With Myeloma
ASH 2023: Large Real-World Study of Bispecific T-Cell Engager in Resistant Myeloma
ASH 2023: Four Drugs, Two Transplants, One Study’s Results in High-Risk Myeloma
Long-Term Study Gets to the Heart of Cardiovascular Issues After HSCT
Daratumumab-Based Regimen for Lenalidomide-Refractory Myeloma: An Italian Perspective
OCEAN and HORIZON Trials: More Benefit Than Risk With Melflufen Plus Dexamethasone in Myeloma?
Mount Sinai Receives $7 Million Grant for High-Risk Multiple Myeloma Research
Is ASCT Feasible in Selected Older Patients With Multiple Myeloma?
ASCO Quality 2023: When Are Older Black and White Patients With Myeloma Initiating Therapy?
Brazilian Experience With COVID-19 Infections in Patients With Myeloma
ASCO Quality 2023: Electronic Platform for Gathering Social Determinants of Health in Myeloma
ASCO Quality 2023: Caring for Patients With Active Myeloma at Home
ASCO Quality 2023: Antiresorptive Therapy and Myeloma-Related Skeletal Disease
ASCO Quality 2023: Surveyed Patients Balance Risks and Benefits of Myeloma Treatment
Can Health of the Immune System Help Predict the Duration of Remission in Myeloma?
Final Analysis of GRIFFIN Supports Quadruplet Option in Multiple Myeloma
Single-Fraction Radiotherapy Plus PD-1 Inhibitor for Resistant Myeloma: Phase II Results
ASTRO 2023: Impact of Radiation Therapy in a New Era of Myeloma Management
What Drives Relapse After Targeted Immunotherapies for Myeloma?
ASTRO 2023: Tailoring Palliative Radiotherapy for Multiple Myeloma
2023 NCCN Hem: Revisiting Risk Stratification in Newly Diagnosed Myeloma
2023 NCCN Hem: Adding Immunotherapeutic Strategies to the Management Mix in Myeloma
Clinical Activity With Mezigdomide Plus Dexamethasone Reported in Resistant Myeloma
Standard Marrow Versus MRD Testing: Guiding Treatment Decisions in Myeloma
SOHO 2023: Final Overall Survival Trial Update on Combination Therapy in Myeloma
Study in France and Algeria: Unexpected Survival Similarities After ASCT in Myeloma
SOHO 2023: Personalized, Multidisciplinary Approach to Managing Myeloma in Frail Adults
Motixafortide Plus Filgrastim Approved by FDA for ASCT in Multiple Myeloma


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.